Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
38229
CAS Number:
755037-03-7
Regorafenib
Purity:
≥ 98% (HPLC)
Documents
$129.19 /25MG
Pack Size Availability Price
Request Bulk Quote
Product Information

Regorafenib is a potent multi-kinase inhibitor that plays a crucial role in the treatment of various cancers, particularly colorectal cancer and gastrointestinal stromal tumors. This compound functions by inhibiting several protein kinases involved in tumor growth and angiogenesis, making it a valuable therapeutic agent in oncology. Regorafenib's unique mechanism of action allows it to target multiple pathways, providing a strategic advantage over other treatments that may only focus on a single target. Its efficacy has been demonstrated in clinical settings, where it has been shown to extend survival rates in patients with advanced-stage cancers.

In addition to its primary applications in oncology, Regorafenib is also being explored for its potential use in combination therapies, enhancing the effectiveness of existing treatments. Researchers appreciate its ability to overcome resistance mechanisms often seen with other cancer therapies, making it a promising candidate for future studies. With its well-documented safety profile and significant therapeutic benefits, Regorafenib continues to be a focal point of cancer research and treatment strategies.

CAS Number
755037-03-7
Purity
≥ 98% (HPLC)
Molecular Formula
C21H15ClF4N4O3
Molecular Weight
482.82
MDL Number
MFCD16038047
PubChem ID
11167602
Melting Point
207 - 209 °C
Appearance
White to light yellow to light orange powder to crystal
Conditions
Store at < 0 °C
General Information
CAS Number
755037-03-7
Purity
≥ 98% (HPLC)
Molecular Formula
C21H15ClF4N4O3
Molecular Weight
482.82
MDL Number
MFCD16038047
PubChem ID
11167602
Melting Point
207 - 209 °C
Appearance
White to light yellow to light orange powder to crystal
Conditions
Store at < 0 °C
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
No
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

Regorafenib is widely utilized in research focused on:

  • Cancer Treatment: Primarily used as an oral medication for treating metastatic colorectal cancer and gastrointestinal stromal tumors, offering patients a targeted therapy option that can improve survival rates.
  • Combination Therapy: Often combined with other cancer treatments to enhance efficacy, allowing for a multi-faceted approach to combatting tumors, which can be crucial for patients with complex cancer profiles.
  • Research in Oncology: Serves as a valuable tool in clinical trials and studies aimed at understanding resistance mechanisms in cancer, helping researchers develop more effective therapies.
  • Targeting Multiple Pathways: Its ability to inhibit various kinases involved in tumor growth and angiogenesis makes it a versatile option in drug development, providing insights into multi-target strategies.
  • Patient Management: Helps healthcare professionals in managing treatment plans for patients with advanced cancers, offering a well-studied option that can be tailored to individual patient needs.

Citations